Researchers find better patient-reported quality of life in women who received pelvic IMRT

NewsGuard 100/100 Score

NRG Oncology investigators report better patient-reported quality of life measures for women who received intensity modulated radiation therapy (IMRT) for their pelvic radiation therapy (RT) than those who received standard RT. NRG-RTOG 1203 was designed to assess if the IMRT, by reducing the amount of radiation received by the normal bowel and bladder structure, could decrease side effects for women receiving pelvic radiation. An analysis of NRG-RTOG 1203: A Phase III Randomized Trial Comparing Patient Reported Toxicity and Quality of Life (QOL) During Pelvic IMRT as Compared to Conventional RT, confirmed their hypothesis and the study was presented at the 2016 American Society for Radiation Oncology (ASTRO) Annual Meeting.

In this trial, 278 women requiring post-operative pelvic radiation were randomized to receive either IMRT or standard RT. Treatment with IMRT or standard RT was delivered once daily, 5 days a week for 5-6 weeks. To measure toxicity, patients completed questionnaires about bowel and bladder function and quality of life prior to and during treatment using the Expanded Prostate Cancer Index Composite (EPIC) scale, the FACT-Cx tool and the PRO-CTCAE measurement system.

After 5 weeks of radiation, patients who received IMRT had better bowel and bladder functions scores than patients who received standard RT and required fewer anti-diarrheal medications. Quality of life measures showed less decline for patients treated with IMRT as compared to patients receiving standard RT. Continued follow-up is ongoing to determine if differences in acute toxicity result in lower rates of long-term toxicity.

"This trial has challenged the current practice for the treatment of women with endometrial and cervical cancers," says Walter J. Curran Jr., MD, an NRG Oncology Group Chair and Executive Director of the Winship Cancer Institute of Emory University. "Congratulations to the entire study team and NRG Oncology for continuing to improve the standard of care and quality of life for these patients."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How Artificial General Intelligence can transform radiation oncology